Topcon Healthcare has announced a strategic investment in Senseye, Inc, a company developing a mental health diagnostic platform powered by ocular biomarkers.

According to a press release issued by Topcon, Senseye technology uses AI and computer vision to analyze ocular metrics such as pupil dynamics and eye movement, captured via a smartphone camera. The data are translated into validated digital biomarkers to support diagnosis and monitoring of posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and generalized anxiety disorder (GAD). 

Topcon said this is the company's first investment in technology for mental health and neuropsychiatry. By leveraging the eye as a noninvasive window into the brain, Senseye technology supports the company's Healthcare from the Eye initiative to facilitate early detection of debilitating, chronic diseases enabling earlier, more effective, and less costly interventions. 

According to Topcon, the Senseye solution will enable primary care physicians to incorporate objective mental health screening into routine exams, particularly in underserved settings where behavioral health specialists are scarce. This technology will also allow eyecare providers to identify and flag potential neuropsychiatric concerns during routine eye exams and refer patients as needed to primary care for additional evaluation, the company said. 

According to Topcon, the collaboration lays the groundwork for new diagnostic modules within Harmony, Topcon's connected care platform, which already integrates imaging, AI analytics, and data sharing across clinical settings. By embedding Senseye’s technology into Harmony, Topcon said it aims to provide clinicians with a more holistic understanding of each patient’s mental and physical health status, captured through the eye.